Franklin Genomic Advancements ETF (HELX)

Assets	$22.84M
Expense Ratio	0.50%
PE Ratio	33.21
Shares Out	600,000
Dividend (ttm)	n/a
Dividend Yield	n/a
Ex-Dividend Date	n/a
Payout Frequency	n/a
Payout Ratio	n/a

Volume	2,447
Open	37.72
Previous Close	38.06
Day's Range	37.31 - 37.72
52-Week Low	23.74
52-Week High	38.11
Beta	1.06
Holdings	68
Inception Date	Feb 25, 2020

About HELX

Fund Home Page

The Franklin Genomic Advancements ETF (HELX) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed portfolio of global equity securities of companies relevant to genomic discovery. HELX was launched on Feb 25, 2020 and is issued by Franklin Templeton.

• Asset Class: Equity
• Category: Health
• Region: Global
• Stock Exchange: BATS
• Ticker Symbol: HELX
• ETF Provider: Franklin Templeton

Top 10 Holdings

44.58% of assets

Name	Symbol	Weight
Guardant Health, Inc.	GH	6.83%
Natera, Inc.	NTRA	6.82%
Insmed Incorporated	INSM	4.89%
Medpace Holdings, Inc.	MEDP	4.53%
Krystal Biotech, Inc.	KRYS	3.90%
Alnylam Pharmaceuticals, Inc.	ALNY	3.85%
Adaptive Biotechnologies Corporation	ADPT	3.84%
BridgeBio Pharma, Inc.	BBIO	3.45%
United Therapeutics Corporation	UTHR	3.31%
Ligand Pharmaceuticals Incorporated	LGND	3.16%

Performance

HELX had a total return of 20.31% in the past year, including dividends. Since the fund's inception, the average annual return has been 7.95%.